Tasly Biopharmaceuticals Co., Ltd.

Ruijing Huang

Jian Li

Yan Chen

Xiaohui Ma

Yibo Wang

Xiaodan Cao

Lihua Zhang

Pengyin Wang

Baoqing Fan

Wenlei Li

The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3), or (HM-3)-Linker-Fc(IgG)-Linker-(HM-3). The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.

HM-3 fusion protein and application thereof

Growing community of inventors

Shanghai, China

Ruijing Huang